Ye Weiguo sold 3,500 shares of GYRE THERAPEUTICS, INC. at $6.08 for −$21.3k on May 22, 2026

Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Chief Operating Officer
Chief Operating Officer
Filed May 27, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
−$21,280Shares × reported price
Shares traded
3,500Common Stock
Price per share
$6.08Reported price. Read footnotes for ranges.
% of reported position traded
0.5%This security and ownership context
Holdings after
700,000Direct
Trade date
May 22, 2026Sell
Filed
May 27, 2026, 4:01 PM ET5-day reporting delay
Accession
0001140361-26-022980Code S · Transaction 89644
How reported position traded is calculated

Shares sold ÷ (holdings after + shares sold). Estimated position before: 703,500 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
May 22, 2026Option exercise3,500$0.75$2,625Trade 89643
May 26, 2026Option exercise4,000$0.75$3,000Trade 89645
May 22, 2026Option exercise3,500$0.00$0Trade 89647
May 26, 2026Option exercise4,000$0.00$0Trade 89648
May 26, 2026Sell4,000$6.10−$24,400.40Trade 89646
6 transaction rows in this filing. Joint filers share the same rows.

GYRE price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
GYRE · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +31%1w ago +11%1d ago +4.4%
Returns since7d −3.9%30d +6.3%90d +13%180d1y

Footnotes in full

F1: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $6.04 to $6.1051. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F2: These options are vested in full.